New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 11, 2013
10:23 EDTKBR, JEC, FLRFluor, Jacobs decline after competitor cuts guidance
Shares of engineering and construction companies Fluor (FLR) and Jacobs Engineering Group (JEC) are falling after one of their competitors, KBR (KBR), lowered its fiscal 2012 earnings per share guidance. KBR now expects its fiscal 2012 EPS to be $1.95-$2.10 excluding a goodwill charge for the third quarter, down from its previous forecast of $2.60-$2.80. The company also forecast that its fiscal 2013 EPS will be $2.45-$2.90, below analysts' consensus estimate of $2.96. KBR blamed the reduction in its 2012 guidance on project charges it expects to take for its Minerals and U.S. Construction businesses, along with higher than expected labor costs. The company expects its business to strengthen in the second half of 2013 as existing projects continue to advance. In mid-morning trading, Fluor dropped 1.44% to $61.73, Jacobs Engineering slid 1.15% to $44.67, and KBR tumbled 8.13% to $29.40.
News For FLR;JEC;KBR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
16:18 EDTFLRFluor-led JV selected as preferred bidder for Bergstrom Expressway in Austin, TX
Subscribe for More Information
08:14 EDTKBRKBR, Exelus sign technology licensing agreement
Subscribe for More Information
May 26, 2015
20:41 EDTFLRJohnson Rice to hold a conference
Subscribe for More Information
07:08 EDTKBRKBR awarded contract by ToAZ to revamp seven ammonia plants in Togliatti
Subscribe for More Information
May 20, 2015
08:44 EDTFLRFluor shares attractive amid transition to nat gas, says Sterne Agee CRT
Subscribe for More Information
May 19, 2015
07:45 EDTJECJacobs Engineering receives contract from Bristol-Myers
Jacobs Engineering (JEC) received a contract from Bristol-Myers Squibb Company (BMY) to provide construction management services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. Jacobs is also providing architectural and engineering services for the facility, which is being built to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
May 18, 2015
06:34 EDTKBRKBR wins appeal as Court of Appeals reverses $81M judgement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use